Varicose veins result in loss of work days, disability and significant impairment in quality of life. 1 Studies have shown that treatment of symptomatic varicose veins is cost-effective. 5, 6 In a randomised controlled study comparing conservative management to surgery among patients with uncomplicated varicose veins, the incremental cost per quality-adjusted life year (QALY) for surgery was £4682 with a 70% chance of being costeffective at the National Institute for Health and Care Excellence (NICE) threshold of £20,000 per QALY. 4 Cost-effectiveness has also been demonstrated for minimally invasive techniques. 6 Despite evidence for cost effectiveness, treatment provision by healthcare funders is often influenced by perceived treatment costs, namely the cost of the intervention. This can have a direct impact, for example restricting funding solely for the treatment of more advanced disease classes, such as venous ulceration or in the presence of bleeding varicosities. 7 This was the case in England prior to the 2013 NICE guidance implementation, when treatment for uncomplicated varicose veins was not routinely recommended. This period was associated with a potential reduction in annual varicose veins procedures of 34% between 1998 and 2008. 8 Despite a more proactive approach advocated by the latest NICE guidance 9 recommending interventional treatment of symptomatic C2 disease, there is evidence that interventional therapy is not always implemented by individual clinical commissioning groups (CCGs), 10 resulting in differences in the management of primary varicose vein disease across the UK.
Limited evidence for compression in uncomplicated C2 disease exists, 11 with current Society for Vascular Surgery/American Venous Forum, 2 European 12 and NICE 9 guidance recommending its use only when interventional treatment is not suitable or in pregnancy; despite this, in many places compression therapy remains a common first management option. 9 Its non-invasive nature and lower perceived cost compared to interventional treatment (estimated annual cost per person of £182/$225), combined with positive physiological and haemodynamic effects (including enhancing venous return, lymphatic drainage and improving tissue oxygenation) make them a safe conservative option. 13 However, not all is as it seems; compression stockings, despite being non-invasive in nature, may cause significant complications, including contact dermatitis, pressure necrosis and impaired lower limb perfusion. Despite the true incidence of these adverse effects being uncertain, a survey study of Scottish surgeons reported 73 cases over a five-year period.
14 Undesirable appearance, difficult application (particularly in the elderly) and excessive heat production have all been suggested to lead to an estimated noncompliance rate of up to 65%. 11 This results in poor outcomes and raises questions regarding their longerterm cost-effectiveness in this cohort of patients. 8 Compression therapy improves venous ulcer healing; 15 however, the lack of consensus regarding its use in C2 disease is evidenced by a recent Cochrane Review, which highlights the absence of robust randomised controlled trials (RCTs) evaluating the effectiveness of compression therapy in patients with uncomplicated varicose veins. 11 Of the seven RCTs included in the analysis, six primarily aimed to establish the optimal level of compression in patients with uncomplicated varicose veins. Although the majority of these studies reported subjective improvement in symptoms, the lack of appropriate control group introduced significant bias. Furthermore, enrolment of study participants from surgical waiting lists considerably decreased the generalisability of the reported findings. Arguably, individuals in this cohort were more likely to comply with the proposed intervention.
Collectively, the current evidence raises the important question of whether a subgroup of patients is receiving suboptimal care that does not comply with national guidance. The increasing scarcity of resources within the healthcare system may present a barrier to the interventional management of uncomplicated varicose veins in the future. Patients who are not candidates for invasive treatment may therefore be managed conservatively with compression hosiery, with little evidence for its clinical and cost-effectiveness, its impact on both generic and disease-specific quality of life, and its role in preventing disease progression.
The lack of data on the clinical benefits of compression in this group of patients raises the question that, perhaps, we are just deferring the inevitable by waiting for patients to develop signs of advanced chronic venous insufficiency, which is significantly more expensive to manage. 16 Considering the reported 4.3% annual progression rate, 4 the cost of treating patients with higher CEAP stages often involves procedural costs (e.g. £975 for endovenous laser ablation 6 ), and the cost of ongoing skin and ulcer care in the case of C6 disease, with an estimated expense of £1872 per patient; 9 venous leg ulceration alone is responsible for an estimated 2% expenditure of the annual national healthcare budget in Western societies. 16 Prevention of disease progression, and development of venous ulceration, is therefore likely to be instrumental in reducing the economic burden of CVD.
The rather unproven effectiveness of compression stockings is on principle largely dependent on patient compliance. This directly impacts on the subgroup of individuals who could potentially benefit from such non-invasive therapy. Considering the cost of managing chronic venous disease, and the lack of evidence on long-term effectiveness of compression, such treatment approaches should potentially be avoided in patients at higher risk of disease progression.
Undoubtedly, a large RCT is required to assess the potential clinical and cost-effectiveness benefits of compression therapy in patients with uncomplicated C2 disease of any origin, whether saphenous or nonsaphenous. This will help simplify the patient management pathway and provide evidence for or against a very simple intervention that significantly impacts on those who need to comply with it.
